MAG and chronic inflammatory demyelinating polyradiculoneuropathy: About 50–70% of DADS-M patients have anti-myelin associated glycoprotein (MAG) antibody comprising a discrete entity with distinctive pathology and treatment responsiveness compared to CIDP (5, 8).